If, in the past, trastuzumab did not improve the outcomes of patients with HER2-low BC, novel and more potent anti-HER2 agents, such as ADCs, paved the way to new treatment options in the metastatic setting [40,41,42,43]. The gene discussed is ERBB2; the disease is breast cancer.